Biocon’s step down subsidiary bags contract from Malaysia to supply human insulin

26 Apr 2022 Evaluate

Biocon’s subsidiary -- Biocon Biologics’ arm Biocon Sdn. Bhd. in Malaysia has been awarded a three-year contract, valued at $90 million (MYR 375 million), for its recombinant human insulin brand Insugen, by the Ministry of Health (MoH), Malaysia.

Biocon Sdn. Bhd. will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn. Bhd. (DMktg), a subsidiary of Duopharma Biotech, a leading pharmaceutical & biotech company in Malaysia. Biocon Biologics' Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

366.40 -6.25 (-1.68%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×